Remus Pharmaceuticals (NSE:REMUS) ROCE % : 39.17% (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Remus Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Remus Pharmaceuticals's annualized ROCE % for the quarter that ended in Sep. 2024 was 39.17%.

Remus Pharmaceuticals ROCE % Historical Data

The historical data trend for Remus Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Remus Pharmaceuticals ROCE % Chart

Remus Pharmaceuticals Annual Data

Trend

Mar20

Mar21

Mar22

Mar24

ROCE %

47.31

48.37

91.90

56.38

Remus Pharmaceuticals Semi-Annual Data
	Mar20	Mar21	Mar22	Sep23	Mar24	Sep24
ROCE %	Get a 7-Day Free Trial			-	-	52.54	48.10	39.17

Remus Pharmaceuticals ROCE % Calculation

Remus Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2022 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2022 )		(A: Mar. 2024 )
	=	322.776	/	( ( (159.093 - 91.99)	+	(2572.727 - 1494.818) )	/ 2 )
	=	322.776	/	( (67.103	+	1077.909)	/ 2 )
	=	322.776	/	572.506
	=	56.38 %

Remus Pharmaceuticals's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Mar. 2024 )		(Q: Sep. 2024 )
	=	459.95	/	( ( (2572.727 - 1494.818)	+	(2213.912 - 943.54) )	/ 2 )
	=	459.95	/	( ( 1077.909	+	1270.372 )	/ 2 )
	=	459.95	/	1174.1405
	=	39.17 %

(1) Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

Remus Pharmaceuticals (NSE:REMUS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Remus Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of Remus Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Remus Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Remus Pharmaceuticals Ltd (NSE:REMUS) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ambli bopal Road, 1101 to 1103, South Tower, One 42, Behind Ashok Vatika, Near Jayantilal Park BRTS, Ahmedabad, GJ, IND, 380054

Website

https://www.remuspharma.com

Remus Pharmaceuticals Ltd is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. The company also deals in API (Active Pharmaceutical Ingredient). It also provides technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries. Remus Pharmaceuticals market niche medicinal combinations. It exports generic drugs by conducting intensive market research in the pharmaceutical industry to expand its product portfolio.

Remus Pharmaceuticals Headlines

No Headlines